Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy

[1]  J. Jett,et al.  A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Yoshizawa,et al.  Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[3]  D. S. Li,et al.  Involvement of Akt1/protein kinase Bα in tumor conditioned medium-induced endothelial cell migration and survival in vitro , 2009, Journal of Cancer Research and Clinical Oncology.

[4]  G. Peters,et al.  Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients , 2008, British Journal of Cancer.

[5]  F. Barlesi,et al.  The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[7]  Y. Bang,et al.  ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. , 2007, Lung cancer.

[8]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[9]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[10]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[11]  J. Mackey,et al.  Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10 , 2007, Clinical Cancer Research.

[12]  Elisabeth Brambilla,et al.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.

[13]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[14]  Y. Bang,et al.  Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation , 2006, Clinical Cancer Research.

[15]  R. Guo,et al.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. , 2006, Lung cancer.

[16]  W. Travis,et al.  Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Testa,et al.  Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.

[18]  M. Berger,et al.  Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors , 2005, Cell cycle.

[19]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[21]  S. Pinder,et al.  E‐cadherin expression in invasive non‐lobular carcinoma of the breast and its prognostic significance , 2005, Histopathology.

[22]  J. McCubrey,et al.  Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. , 2005, International journal of oncology.

[23]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[24]  Young Tae Kim,et al.  Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Bepler,et al.  ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. , 2005, Chest.

[26]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[27]  J. McCubrey,et al.  Phosphatidylinositol 3′-Kinase Activation Leads to Multidrug Resistance Protein-1 Expression and Subsequent Chemoresistance in Advanced Prostate Cancer Cells , 2004, Cancer Research.

[28]  K. Matsuo,et al.  Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-analysis of Randomized Controlled Trials , 2006 .

[29]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[30]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[31]  J. Jett,et al.  Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  S. Vicent,et al.  ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours , 2004, British Journal of Cancer.

[33]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[34]  T. Mukohara,et al.  Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). , 2003, Lung cancer.

[35]  G. Giaccone,et al.  Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. Konopleva,et al.  Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  N. Anderson,et al.  ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR‐positive cancer cell lines with or without erbB2 overexpression , 2001, International journal of cancer.

[38]  J. Baselga,et al.  Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. , 2001, Seminars in oncology.

[39]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[40]  T. Rebbeck,et al.  BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Stephen L. Abrams,et al.  Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. , 2006, Advances in enzyme regulation.